Interventions of interest: Hand-held and automated breast ultrasound Digital breast tomosynthesis (DBT) Magnetic resonance imaging (MRI) Following a negative mammogram, many women with dense breast tissue face a decision: whether to receive additional screening, and if so, what modality to use. Many mammography facilities are now informing women with dense breasts about the potential for […]
Intervention of interest: Programs to integrate behavioral health into the primary care setting Providers in the US health care system often assess and treat patients with physical health conditions and behavioral health conditions (e.g., mental health and substance use disorders) in siloes, yet physical and behavioral health are inextricably linked. Up to 70% of physician […]
Interventions of interest, 2019 review: Esketamine (SPRAVATO®, Janssen) Major depressive disorder (MDD) is a common and debilitating condition; on an annual basis, it is estimated that nearly 14 million Americans will have at least one episode of MDD. While definitions of so-called “treatment-resistant” depression vary, this generally refers to patients with persistent depression after attempted […]
Interventions of interest, 2011 review: Repetitive transcranial magnetic stimulation, electroconvulsive therapy, vagus nerve stimulation, and cognitive-behavioral therapy/interpersonal therapy Major depressive disorder (MDD) is a common and debilitating condition; on an annual basis, it is estimated that nearly 14 million Americans will have at least one episode of MDD. While definitions of so-called “treatment-resistant” depression vary, this […]
Intervention of interest: Diabetes prevention programs The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus each year. The direct medical costs of diabetes were estimated to be $176 billion in 2012. Interventions to prevent diabetes have the potential to save […]
Treatments of Interest: deflazacort (Emflaza®, PTC Therapeutics) eteplirsen (Exondys 51®, Sarepta) golodirsen (Vyondys 53®, Sarepta) Duchenne muscular dystrophy (DMD) is a genetically inherited neuromuscular disease that almost entirely affects boys and results in a progressive loss of muscle function, resulting in progressive weakness and eventual death usually from cardiac and respiratory failure. It is the […]
Interventions of Interest: elagolix (ORILISSA®, AbbVie) Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well as infertility. Endometriosis affects between four and ten million women of reproductive age in the US. Because elagolix’s price aligns with clinical benefit only when compared to […]
Interventions of interest: Simeprevir (Olysio®, Janssen Products, LP) + sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) Ledipasvir/sofosbuvir (Harvoni®, Gilead Sciences, Inc.) Daclatasvir (Daklinza™, Bristol-Myers Squibb Company) + sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) Paritaprevir/ritonavir/ombitasvir + dasabuvir with ribavirin (Viekira Pak™, AbbVie, Inc.) Simeprevir (Olysio®, Janssen Products, LP)+ pegylated interferon and ribavirin Sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) + ribavirin […]
Interventions of interest: Sofosbuvir (Sovaldi®, Gilead Sciences, Inc.)Simeprevir (Olysio®, Janssen Products, LP) Chronic hepatitis C is a common infection that is a major cause of chronic liver disease, liver failure, and hepatocellular carcinoma (HCC), and it is the leading indication for liver transplantation in the Western world. Prior to 2011, the combination of pegylated interferon […]
Interventions of Interest: tisagenlecleucel (KymriahTM , Novartis) axicabtagene ciloleucel (YescartaTM, Kite Pharma) ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. The policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit there will be changes needed in future pricing, payment, and […]